Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. is poised for a positive financial outlook driven by a significant increase in the average selling price (ASP) of its flagship product, Apligraf, which has risen fourfold, highlighting its competitive positioning within the advanced wound care market. While the company's performance has experienced variability due to market dynamics and forthcoming changes in reimbursement structures, recent results indicate a trend of improving unit volumes and solid operational performance during the latter part of 2026. Furthermore, an upward adjustment in the reimbursement rate for 2026 reflects favorable market conditions that may contribute to enhanced valuation and growth prospects for the company's regenerative medicine offerings.

Bears say

Organogenesis Holdings Inc. faces a negative outlook primarily due to anticipated challenges in the Advanced Wound Care market, with the company projecting a significant ~50% year-over-year decline in first-quarter 2026 revenues linked to product sizing waste and excess inventory. The risk factors include lower-than-expected growth in the PuraPly product line, unfavorable pricing changes for Medicare Part B on amniotic products, and increasing competitive pressures that may inhibit market share gains. Additionally, uncertainty surrounding the uptake of new products and the potential for adverse clinical data outcomes further contribute to the pessimistic financial forecast for the company.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.